The FDA is reconsidering its restrictions on compounded peptides and will hold advisory panel meetings, while Roche plans to conduct another trial for the Duchenne muscular dystrophy gene therapy Elevidys to secure European approval. Additionally, Eli Lilly's GLP-1 pill Foundayo has shown promising results in a cardiovascular outcomes trial for diabetes and obesity, with plans to submit it for FDA approval.
The most actionable insight for you is that Eli Lilly plans to submit its GLP-1 pill, Foundayo, for FDA approval by the end of the second quarter, which could be a significant development in the digital health and pharmaceutical sectors, particularly for treatments targeting type 2 diabetes. This submission under the National Priority Review Voucher could accelerate its market entry, making it a potential area for investment or partnership in healthtech and digital therapeutics focused on diabetes management.